by CU Anschutz Medical Campus a, Diagram of trial design. b, Summary of pathological outcomes of all evaluable patients (n = 19 patients). c, Summary of clinical outcomes of patients treated at MTD (n = 18). d, Kaplan–Meier survival curves for overall survival, PFS and local PFS survival for patients treated at MTD (n = 18 patients). e, A plot of...
The combination therapy with TLR agonist and anti-PD-1 agent activates CD8+ T cells (red) in the tumors. Checkpoint inhibitor-based immunotherapy has been shown to be very effective in recurrent and metastatic head and neck cancer but only in a minority of patients. University of California San Diego School of Medicine researchers may have found...
The immunotherapy nivolumab is kinder than chemotherapy for people with advanced head and neck cancer – easing many of the negative effects of the disease on patients’ quality of life. Both head and neck cancer and the treatment for it can have a huge impact on patients – affecting their speech, breathing, eating and drinking,...
